Vitamin D Deficiency – Evidence‑Based Guideline Summary

Causes and Contributing Factors

• Inadequate exposure to natural sunlight is the principal cause of vitamin D deficiency because cutaneous UVB‑driven synthesis provides the majority of the body’s vitamin D stores. 1
• Use of sunscreen with SPF 30 suppresses cutaneous vitamin D production by >95 %. 1
• Residence at latitudes ≥ 33° (north or south) results in minimal or absent cutaneous vitamin D₃ synthesis during most winter months. 1
• Modern lifestyle patterns that expose < 5 % of skin surface to sunlight and that rely on UVB‑blocking sunscreens markedly reduce endogenous vitamin D production. 2
• Dietary intake of vitamin D is limited; fatty fish (e.g., salmon, mackerel, herring) are the only natural foods that provide appreciable amounts. 1
• In the United States and Canada, fortified foods (milk, breads, orange juice, cereals) constitute the primary dietary source of vitamin D. 1
• Plant‑derived vitamin D₂ (ergocalciferol) is virtually absent from typical diets. 2

High‑Risk Populations

• Individuals with dark skin require 3–5 × longer sun exposure to generate the same cutaneous vitamin D as light‑skinned persons. 1
• African‑American adults have a 70.6 % prevalence of serum 25(OH)D ≤ 20 ng/mL, compared with 21.7 % in white adults. 3
• Older adults exhibit reduced skin 7‑dehydrocholesterol content and diminished renal 1‑α‑hydroxylase activity, lowering endogenous vitamin D synthesis. 4
• Up to 50 % of institutionalized elderly residents have insufficient vitamin D levels. 4
• Serum 25(OH)D concentrations inversely correlate with body‑mass index > 30 kg/m²; higher adiposity sequesters vitamin D in fat tissue. 1
• Malabsorptive bariatric procedures (e.g., Roux‑en‑Y gastric bypass) markedly impair intestinal absorption of fat‑soluble vitamin D. 4
• Chronic kidney disease with estimated GFR < 60 % reduces renal 1‑α‑hydroxylase activity, limiting conversion to active 1,25(OH)₂D. 4
• Nephrotic syndrome leads to urinary loss of vitamin D‑binding protein‑bound 25(OH)D. 4
• Severe hepatic disease diminishes hepatic 25‑hydroxylase activity, impairing formation of 25(OH)D. 4
• Enzyme‑inducing anti‑epileptic drugs accelerate catabolism of both 25(OH)D and 1,25(OH)₂D. 4
• Antiretroviral regimens for HIV infection increase vitamin D metabolism, lowering serum levels. 5

Clinical Impact

• Vitamin D deficiency is associated with muscle weakness and functional impairment in older adults. 4
• Supplementation with vitamin D reduces the incidence of falls by approximately 50 % in at‑risk elderly populations. 4
• Low serum 25(OH)D concentrations correlate with a higher risk of nursing‑home admission among older individuals. 4

Diagnostic Recommendations

• Measurement of serum 25‑hydroxyvitamin D (25(OH)D) is the preferred laboratory test for assessing vitamin D status. 1
• Serum 1,25‑dihydroxyvitamin D (1,25(OH)₂D) should not be used for screening; it is reserved for evaluation of specific disorders of vitamin D or phosphate metabolism. 6
• Diagnostic thresholds:
  
  • Deficiency – 25(OH)D < 20 ng/mL (< 50 nmol/L).
  • Insufficiency – 25(OH)D 20–30 ng/mL (50–75 nmol/L).
  • Optimal – 30–50 ng/mL (75–125 nmol/L). [1][6]7
• Population‑wide screening for vitamin D deficiency is not supported by current evidence. 3
• Targeted testing is recommended for high‑risk groups, including:
  
  • Patients with malabsorption syndromes.
  • Post‑bariatric surgery individuals.
  • Chronic kidney disease patients.
  • Persons receiving medications that alter vitamin D metabolism (e.g., enzyme‑inducing anticonvulsants, antiretrovirals).
  • Institutionalized or homebound individuals. [6][5]7
• Analytical considerations: assay variability between laboratories ranges from 10 % to 20 %; classification of deficiency versus sufficiency may differ by 4 %–32 % depending on the assay employed. [3][8]
• Inflammatory states can lower 25(OH)D levels because the metabolite behaves as a negative acute‑phase reactant. 8

Management and Prevention

• Endocrinology specialty societies (American College of Endocrinology and American Association of Clinical Endocrinologists) advise maintaining serum 25(OH)D > 30 ng/mL to prevent secondary hyperparathyroidism. 4
• Parathyroid hormone (PTH) concentrations begin to rise when 25(OH)D falls to approximately 31.2 ng/mL (78 nmol/L). 4
• Achieving target vitamin D levels generally requires daily supplementation of 600–2,000 IU vitamin D₃, adjusted to individual risk factors and baseline status. 4

Ethnic and Physiologic Considerations

• Although African‑American individuals often have lower total serum 25(OH)D, bioavailable 25(OH)D (accounting for vitamin‑binding protein differences) may be comparable to that of white individuals. 3
• Despite a higher prevalence of low total 25(OH)D, African‑American adults experience roughly half the fracture risk of white adults, suggesting that total serum measurements may not fully reflect functional vitamin D status across ethnic groups. 3

Vitamin D Deficiency: Guideline‑Based Implications for Insomnia Assessment

1. Scope of Current Clinical Practice Guidelines

• The Endocrine Society (2011) recommends vitamin D assessment and treatment to prevent muscle weakness, functional impairment, falls, fractures, osteomalacia, rickets, and secondary hyperparathyroidism; these are the only established clinical consequences of deficiency. Strong recommendation for skeletal and muscular outcomes. 9
• The U.S. Preventive Services Task Force (USPSTF, 2015) states that although low vitamin D levels have been reported to associate with depression and other outcomes, the evidence is insufficient to determine whether treating asymptomatic deficiency improves any clinical outcome, including sleep. Insufficient evidence for routine screening. 10
• Both the Endocrine Society and USPSTF guidelines do not list insomnia as a recognized consequence of vitamin D deficiency. [9][10]

2. Mechanistic Evidence Supporting a Sleep Link

• Vitamin D receptors are present in brain regions that regulate circadian rhythms and sleep, indicating a plausible biological pathway for vitamin D to influence sleep architecture. Observational mechanistic data. 11

3. Recommendations on Population Screening

• USPSTF explicitly recommends against population‑based vitamin D screening because benefits on clinical outcomes, including sleep, remain unproven. Insufficient evidence for universal screening. [10][12]

4. Laboratory Considerations

• Serum 25‑hydroxyvitamin D assays show inter‑laboratory variability of 10–20%, and the proportion of individuals classified as deficient can differ by 4–32% depending on the assay used, limiting the reliability of a single measurement. Laboratory variability. 13

5. Targeted Testing in Patients With Insomnia

• Vitamin D testing is reasonable in individuals with insomnia who also have established risk factors for deficiency, such as malabsorption syndromes, post‑bariatric surgery status, chronic kidney disease (eGFR < 60 mL/min/1.73 m²), dark skin pigmentation, institutionalization, obesity (BMI > 30 kg/m²), or use of enzyme‑inducing anticonvulsants/antiretrovirals. Guideline‑based indication. [14][9]
• Additional testing is warranted when insomnia co‑exists with symptoms suggestive of deficiency (e.g., muscle weakness, bone pain, frequent falls, secondary hyperparathyroidism). Guideline‑based indication. 9

All facts are derived from cited guideline documents or peer‑reviewed mechanistic studies; strength of evidence is indicated where reported.

USPSTF Recommendations on Vitamin D Screening and Management

Population Screening

• The U.S. Preventive Services Task Force recommends against routine population‑based screening for vitamin D deficiency, stating that current evidence does not demonstrate a proven benefit on clinical outcomes beyond bone health. (Evidence level: insufficient) 15

Treatment of Asymptomatic Deficiency

• The USPSTF concludes that there is insufficient evidence to determine whether treating asymptomatic vitamin D deficiency improves any clinical outcome other than skeletal health, indicating that routine supplementation for non‑bone indications cannot be endorsed. (Evidence level: insufficient) 15

Sun Exposure as Therapy

• The USPSTF advises against using increased sun exposure as a treatment strategy for vitamin D deficiency because of the associated skin‑cancer risk; oral vitamin D supplementation is the preferred approach. (Evidence level: insufficient) 15